Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
SHANGHAI PECHEM
00338
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 9.49%24.19B | 9.10%125.96B | 7.50%81.79B | 8.99%54.01B | 8.06%22.1B | 1.08%115.46B | -2.39%76.08B | -6.25%49.55B | -3.31%20.45B | -2.37%114.22B |
| Special items of operating revenue | -15.39%126.85M | -1.38%719.89M | -5.13%487.61M | -5.92%295.58M | 6.80%149.92M | 26.10%729.94M | 21.13%513.99M | 44.09%314.18M | -1.71%140.38M | -9.17%578.87M |
| Operating income | 9.32%24.32B | 9.03%126.68B | 7.42%82.28B | 8.89%54.3B | 8.06%22.25B | 1.21%116.19B | -2.27%76.6B | -6.05%49.87B | -3.30%20.59B | -2.40%114.8B |
| Operating expenses | -9.55%-19.75B | -9.91%-103.89B | -8.13%-66.92B | -9.29%-43.96B | -9.24%-18.03B | 0.00%-94.53B | 3.88%-61.89B | 8.26%-40.23B | 5.81%-16.5B | 4.03%-94.53B |
| Special items of gross profit | 15.39%-126.85M | 1.38%-719.89M | 5.13%-487.61M | 5.92%-295.58M | -6.80%-149.92M | -26.10%-729.94M | -21.13%-513.99M | -44.09%-314.18M | 1.71%-140.38M | 9.17%-578.87M |
| Gross profit | 9.23%4.44B | 5.44%22.07B | 4.78%14.87B | 7.67%10.04B | 3.13%4.07B | 6.31%20.93B | 4.66%14.19B | 3.53%9.33B | 8.78%3.94B | 6.49%19.69B |
| Selling expenses | 1.95%-688.61M | -13.74%-3.3B | -9.39%-2.24B | -8.81%-1.48B | -12.28%-702.3M | -3.65%-2.9B | 2.82%-2.05B | 4.48%-1.36B | 13.90%-625.47M | 27.38%-2.8B |
| Administrative expenses | -4.50%-1.78B | -6.05%-8.45B | -2.18%-5.36B | -1.31%-3.44B | -4.43%-1.71B | 0.48%-7.96B | -1.93%-5.24B | -0.33%-3.39B | 1.04%-1.63B | 2.03%-8B |
| Research and development expenses | -27.53%-1.32B | -8.82%-6.16B | -8.59%-4.01B | -9.38%-2.55B | -2.13%-1.04B | -5.50%-5.66B | -3.30%-3.69B | -0.02%-2.33B | -2.92%-1.01B | -6.78%-5.37B |
| Profit from asset sales | -106.74%-999K | 1,371.34%505.8M | 9,553.13%91.98M | 628.65%35.68M | 235.73%14.83M | -95.94%34.38M | -100.28%-973K | -78.14%4.9M | -82.52%4.42M | 51.13%847M |
| Revaluation surplus | -39.91%18.44M | 42.27%-267.6M | 120.80%70.72M | 108.03%25.7M | 112.31%30.69M | -47.26%-463.56M | -732.22%-339.98M | -189.95%-319.89M | -179.11%-249.24M | 55.99%-314.79M |
| -Changes in the fair value of other assets | -39.91%18.44M | 42.27%-267.6M | 120.80%70.72M | 108.03%25.7M | 112.31%30.69M | -47.26%-463.56M | -732.22%-339.98M | -189.95%-319.89M | -179.11%-249.24M | 55.99%-314.79M |
| Impairment and provision | -10.27%-166.74M | 25.87%-2.42B | -19.38%-1.5B | -17.86%-944.2M | 27.81%-151.21M | 5.58%-3.26B | 17.31%-1.26B | 49.23%-801.15M | -96.86%-209.47M | 18.43%-3.46B |
| -Other impairment is provision | -10.27%-166.74M | 25.87%-2.42B | -19.38%-1.5B | -17.86%-944.2M | 27.81%-151.21M | 5.58%-3.26B | 17.31%-1.26B | 49.23%-801.15M | -96.86%-209.47M | 18.43%-3.46B |
| Operating interest expense | 35.17%-14.41M | 25.91%-72.81M | 17.51%-58.58M | 13.74%-43.24M | 20.14%-22.24M | -13.58%-98.27M | -12.40%-71.02M | -22.16%-50.13M | -33.83%-27.84M | 0.74%-86.52M |
| Special items of operating profit | 8.84%949.73M | 7.35%4.62B | -1.55%2.92B | -5.51%1.82B | -2.61%872.59M | -16.39%4.31B | 14.45%2.97B | 5.57%1.93B | 16.10%896M | 80.82%5.15B |
| Operating profit | 6.95%1.28B | 35.75%5.78B | 4.59%4.27B | 14.57%3.12B | 24.39%1.19B | -14.09%4.26B | 11.52%4.09B | 26.72%2.72B | -14.97%958.69M | 784.83%4.95B |
| Financing income | 69.59%113.08M | 42.90%-574.06M | -51.27%392.04M | 57.10%-275.26M | -81.29%66.68M | -56.28%-1.01B | 67.15%804.58M | -91.61%-641.69M | 123.19%356.43M | -27.51%-643.34M |
| Financing cost | 19.89%-297.61M | 17.44%-1.29B | 24.99%-983.01M | 21.19%-676.21M | 11.74%-371.49M | 14.80%-1.56B | -6.66%-1.31B | -14.37%-858.02M | -15.80%-420.92M | -4.27%-1.83B |
| Special items of earning before tax | -25.36%4.15M | 96.31%74.52M | -47.09%30.51M | -59.50%18.39M | 7.12%5.55M | 162.93%37.96M | 380.18%57.66M | 228.73%45.41M | 219.97%5.18M | -222.70%-60.32M |
| Earning before tax | 1.96%950.79M | 34.28%5.02B | 0.07%3.67B | 10.34%2.83B | 4.30%932.55M | -1.92%3.74B | 25.12%3.67B | 40.83%2.57B | -0.94%894.13M | 293.03%3.81B |
| After-tax profit from continuing operations | 1.64%645.34M | 14.48%3.09B | -5.78%2.62B | 3.14%2.05B | -0.82%634.93M | 0.83%2.7B | 15.22%2.79B | 33.53%1.98B | -7.63%640.16M | 215.57%2.67B |
| Earning after tax | 1.64%645.34M | 14.48%3.09B | -5.78%2.62B | 3.14%2.05B | -0.82%634.93M | 0.83%2.7B | 15.22%2.79B | 33.53%1.98B | -7.63%640.16M | 215.57%2.67B |
| Minority profit | -22.69%264.9M | -3.27%1.88B | -13.54%1.56B | 0.52%1.23B | -34.26%342.63M | 3.91%1.94B | 12.97%1.8B | 36.15%1.22B | 59.77%521.19M | 49.17%1.87B |
| Profit attributable to shareholders | 30.15%380.44M | 60.30%1.21B | 8.48%1.07B | 7.32%820.75M | 145.69%292.3M | -6.33%752.48M | 19.58%982.09M | 29.55%764.8M | -67.57%118.97M | 122.52%803.35M |
| Basic earnings per share | 30.32%0.0245 | 62.50%0.078 | 7.94%0.068 | 8.16%0.053 | 147.37%0.0188 | -7.69%0.048 | 18.87%0.063 | 28.95%0.049 | -67.66%0.0076 | 122.81%0.052 |
| Diluted earnings per share | 30.32%0.0245 | 62.50%0.078 | 7.94%0.068 | 8.16%0.053 | 147.37%0.0188 | -7.69%0.048 | 18.87%0.063 | 28.95%0.049 | -67.66%0.0076 | 122.81%0.052 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion |
| Auditor | -- | Ernst & Young Huaming Accounting Firm (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Accounting Firm (Special General Partnership) | -- | -- | -- | PwC, PwC Zhongtian Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.